PhillyPharma Archive: January, 2012

Teva shifting from generic label, but.......

Comment icon 0 Comments
Teva Pharmaceutical Industries Ltd., is changing "very fast," chief financial officer Eyal Desheh said at Tuesday's J.P. Morgan Healthcare... Read more

Amid $2.6 trillion in U.S. health-care costs, drug bill was $259 billion, report says

Comment icon 0 Comments
Number crunchers from the Centers for Medicare & Medicaid Services (CMS) say health care spending increases in 2009-2010 slowed down to... Read more

Endo shifting production after Novartis shutdown

Comment icon 0 Comments
Endo Pharmaceuticals of Chadds Ford said Monday it was warning doctors and consumers of possible short-term supply problems with some of its... Read more

Bristol-Myers Squibb buys Inhibitex for $2.5 billion

Comment icon 0 Comments
Bristol-Myers Squibb, which has five New Jersey facilities, said it will buy Inhibitex for approximately $2.5 billion or $26 per share, with... Read more

Sir Andrew Witty

Comment icon 0 Comments
Being a chief executive officer of a global pharmaceutical company is fine and all, but it's nothing like being a knight........we suppose... Read more

Ex-Synthes exec Walsh said to be withdrawing appeal

Comment icon 0 Comments
Former Synthes executive John Walsh was on the road to appealing his five-month prison sentence for involvement in an illegal clinical trial... Read more

Departing Teva CEO says Cephalon is key to company's future

Comment icon 0 Comments
Teva Pharmaceuticals Ltd., announced over the weekend that Shlomo Yanai would retire in May as president and chief executive officer of the... Read more

Teva Pharmaceuticals changes top executive

Comment icon 0 Comments
Teva Pharmaceutical Industries Ltd., which has a big operation in North Wales and is building a facility in North Philadelphia, announced Monday... Read more